{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:11:41Z","timestamp":1790997101967,"version":"4.1.0"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T00:00:00Z","timestamp":1563580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"N\u00eemes University Hospital","award":["AOI GCS MERRI 2010"],"award-info":[{"award-number":["AOI GCS MERRI 2010"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Metastatic melanoma is one of the most aggressive and drug-resistant cancers with very poor overall survival. Circulating melanoma cells (CMCs) were first described in 1991. However, there is no general consensus on the clinical utility of CMC detection, largely due to conflicting results linked to the use of heterogeneous patient populations and different detection methods. Here, we developed a new EPithelial ImmunoSPOT (EPISPOT) assay to detect viable CMCs based on their secretion of the S100 protein (S100-EPISPOT). Then, we compared the results obtained with the S100-EPISPOT assay and the CellSearch\u00ae CMC kit using blood samples from a homogeneous population of patients with metastatic melanoma. We found that S100-EPISPOT sensitivity was significantly higher than that of CellSearch\u00ae. Specifically, the percentage of patients with \u22652 CMCs was significantly higher using S100-EPISPOT than CellSearch\u00ae (48% and 21%, respectively; p = 0.0114). Concerning CMC prognostic value, only the CellSearch\u00ae results showed a significant association with overall survival (p = 0.006). However, due to the higher sensitivity of the new S100-EPISPOT assay, it would be interesting to determine whether this functional test could be used in patients with non-metastatic melanoma for the early detection of tumor relapse and for monitoring the treatment response.<\/jats:p>","DOI":"10.3390\/cells8070755","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T02:55:37Z","timestamp":1563764137000},"page":"755","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells"],"prefix":"10.3390","volume":"8","author":[{"given":"Laure","family":"Cayrefourcq","sequence":"first","affiliation":[{"name":"Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, UPRES EA2415, 34093 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"De Roeck","sequence":"additional","affiliation":[{"name":"Department of Dermatology, N\u00eemes University Hospital, University of Montpellier, 30029 N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, N\u00eemes University Hospital, University of Montpellier, 30029 N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Stoebner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, N\u00eemes University Hospital, University of Montpellier, 30029 N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Fichel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, N\u00eemes University Hospital, University of Montpellier, 30029 N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Garima","sequence":"additional","affiliation":[{"name":"Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, UPRES EA2415, 34093 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Perriard","sequence":"additional","affiliation":[{"name":"UPRES EA2415, University Institute of Clinical Research (IURC), Montpellier University, 34093 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Daures","sequence":"additional","affiliation":[{"name":"UPRES EA2415, University Institute of Clinical Research (IURC), Montpellier University, 34093 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Meunier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, N\u00eemes University Hospital, University of Montpellier, 30029 N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-2903","authenticated-orcid":false,"given":"Catherine","family":"Alix-Panabi\u00e8res","sequence":"additional","affiliation":[{"name":"Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, UPRES EA2415, 34093 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dummer, R., Daud, A., Puzanov, I., Hamid, O., Schadendorf, D., Robert, C., Schachter, J., Pavlick, A., Gonzalez, R., and Hodi, F.S. (2015). A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. J. Transl. Med., 13.","DOI":"10.1186\/1479-5876-13-S1-O5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1039\/C3LC50644D","article-title":"Technologies for detection of circulating tumor cells: Facts and vision","volume":"14","author":"Pantel","year":"2014","journal-title":"Lab Chip"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2010.10.002","article-title":"Methods of detection of circulating melanoma cells: A comparative overview","volume":"37","author":"Nezos","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"van der Toom, E.E., Verdone, J.E., Gorin, M.A., and Pienta, K.J. (2016). Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget.","DOI":"10.18632\/oncotarget.11191"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201303698","article-title":"Biology, detection, and clinical implications of circulating tumor cells","volume":"7","author":"Joosse","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-med-062310-094219","article-title":"Circulating tumor cells and circulating tumor DNA","volume":"63","author":"Schwarzenbach","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molonc.2016.01.009","article-title":"Liquid biopsy: Potential and challenges","volume":"10","author":"Pantel","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Alix-Panabieres, C., and Pantel, K. (2016). Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov.","DOI":"10.1158\/2159-8290.CD-15-1483"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1600274","DOI":"10.1126\/sciadv.1600274","article-title":"Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment","volume":"2","author":"Khoo","year":"2016","journal-title":"Sci. Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","article-title":"Circulating tumor cells: Liquid biopsy of cancer","volume":"59","author":"Pantel","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"Scher","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/annonc\/mdu207","article-title":"Circulating tumour cells as tumour biomarkers in melanoma: Detection methods and clinical relevance","volume":"26","author":"Khoja","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med Oncol. ESMO"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1373\/clinchem.2015.242537","article-title":"Functional Studies on Viable Circulating Tumor Cells","volume":"62","author":"Pantel","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-642-28160-0_6","article-title":"EPISPOT assay: Detection of viable DTCs\/CTCs in solid tumor patients","volume":"195","year":"2012","journal-title":"Recent Results Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1373\/clinchem.2013.202846","article-title":"Capture of viable circulating tumor cells in the liver of colorectal cancer patients","volume":"59","author":"Deneve","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1373\/clinchem.2013.215079","article-title":"Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients","volume":"60","author":"Ramirez","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1586\/14737159.2015.1091729","article-title":"Liquid biopsy in cancer patients: Advances in capturing viable CTCs for functional studies using the EPISPOT assay","volume":"15","author":"Pantel","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39736","DOI":"10.1038\/srep39736","article-title":"Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients","volume":"6","author":"Kuske","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-4939-7144-2_22","article-title":"EpCAM-Independent Enrichment and Detection of Viable Circulating Tumor Cells Using the EPISPOT Assay","volume":"1634","author":"Soler","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.acc.2014.12.002","article-title":"Chapter Two-Circulating Biomarkers in Malignant Melanoma","volume":"Volume 69","author":"Makowski","year":"2015","journal-title":"Advances in Clinical Chemistry"},{"key":"ref_23","first-page":"755","article-title":"Circulating melanoma cells and survival in metastatic melanoma","volume":"38","author":"Rao","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2005.02.007","article-title":"Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients","volume":"299","author":"Brouillet","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1373\/clinchem.2005.049445","article-title":"Detection of Circulating Prostate-Specific Antigen\u2013Secreting Cells in Prostate Cancer Patients","volume":"51","author":"Rebillard","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/jid.2012.468","article-title":"Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma","volume":"133","author":"Khoja","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Pantel, K., and Speicher, M.R. (2015). The biology of circulating tumor cells. Oncogene.","DOI":"10.1038\/onc.2015.192"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","article-title":"Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay","volume":"31","author":"Baccelli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.critrevonc.2014.01.007","article-title":"Detection methods of circulating tumor cells in cutaneous melanoma: A systematic review","volume":"91","author":"Rodic","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_31","first-page":"84","article-title":"Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma","volume":"21","author":"Xu","year":"2016","journal-title":"Oncology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/jid.2010.285","article-title":"Expression of the stem cell markers nestin and CD133 on circulating melanoma cells","volume":"131","author":"Fusi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/jid.2010.377","article-title":"RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells","volume":"131","author":"Kupas","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating human melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature09161","article-title":"Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271","volume":"466","author":"Boiko","year":"2010","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molonc.2016.01.004","article-title":"Functional studies on circulating and disseminated tumor cells in carcinoma patients","volume":"10","author":"Bartkowiak","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4065\/mcp.2011.0287","article-title":"Circulating serologic and molecular biomarkers in malignant melanoma","volume":"86","author":"Palmer","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7150\/jca.10560","article-title":"Use of proteins as biomarkers and their role in carcinogenesis","volume":"6","author":"Zarogoulidis","year":"2015","journal-title":"J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejso.2011.12.005","article-title":"The current status of S-100B as a biomarker in melanoma","volume":"38","author":"Kruijff","year":"2012","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Long, E., Ilie, M., Bence, C., Butori, C., Selva, E., Lalvee, S., Bonnetaud, C., Poissonnet, G., Lacour, J.P., and Bahadoran, P. (2016). High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness. Cancer Med.","DOI":"10.1002\/cam4.661"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","article-title":"Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma","volume":"404","author":"Calapre","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pantel, K., and Alix-Panabieres, C. (2019). Liquid biopsy and minimal residual disease\u2014Latest advances and implications for cure. Nat. Rev. Clin. Oncol.","DOI":"10.1038\/s41571-019-0187-3"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/7\/755\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:07:48Z","timestamp":1760188068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/7\/755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,20]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["cells8070755"],"URL":"https:\/\/doi.org\/10.3390\/cells8070755","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,20]]}}}